PAD plus lenalidomide in multiple myeloma - a promising four-drug regimen in newly diagnosed and advanced disease

被引：0
|
作者：
Schreder, M. [1 ]
Danhof, S. [1 ]
Rasche, L. [1 ]
Strifler, S. [1 ]
Einsele, H. [1 ]
Knop, S. [1 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P870
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [31] Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Kaufman, Jonathan L.
    Mina, Roberto
    Shah, Jatin J.
    Laubach, Jacob P.
    Nooka, Ajay K.
    Lewis, Colleen
    Gleason, Charise
    Sharp, Cathy
    Harvey, R. Donald
    Heffner, Leonard T.
    Richardson, Paul
    Lonial, Sagar
    Orlowski, Robert Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12): : 797 - 803
  • [32] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [33] Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma
    Zhang, Yongqing
    Liu, Hongjuan
    Chen, Xiequn
    Bai, Qingxian
    Liang, Rong
    Shi, Bing
    Liu, Lihui
    Tian, DengMei
    Liu, Mingjuan
    PATHOLOGY & ONCOLOGY RESEARCH, 2014, 20 (04) : 987 - 995
  • [34] Comparison between ixazomib plus cyclophosphamide plus dexamethasone regimen and ixazomib plus dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
    Li, Shutan
    Zhang, Duanzhong
    Yang, Lihua
    Huang, Chunlan
    Niu, Ting
    Gong, Yuping
    CANCER MEDICINE, 2023, 12 (06): : 6523 - 6535
  • [35] Lenalidomide-Related Diarrhea Correlates with Disease Control in Newly-Diagnosed Patients with Multiple Myeloma
    Faiman, Beth
    Kalaycio, Matt
    Samaras, Christy Joy
    Khouri, Jack
    Anwer, Faiz
    Mejia-Garcia, Alex
    Reu, Frederic
    Valent, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E341 - E342
  • [36] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
    Rajkumar, SV
    Hayman, S
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    BLOOD, 2005, 106 (11) : 230A - 231A
  • [37] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (05) : 679 - 686
  • [38] Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma
    Cejalvo, Maria J.
    de la Rubia, Javier
    FUTURE ONCOLOGY, 2015, 11 (11) : 1643 - 1658
  • [39] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Syed, Yahiya Y.
    DRUGS, 2017, 77 (13) : 1473 - 1480
  • [40] A 28 Day Schedule for Lenalidomide Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Chari, Ajai
    Roper, Nitin
    Jagannath, Sundar
    BLOOD, 2011, 118 (21) : 1272 - 1273
12345